The CASP6 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt CASP6 gene expression in the HeLa cervical adenocarcinoma cell line. This polyclonal pool provides a genetically heterogeneous, loss-of-function model for investigating the biological functions of caspase-6 without the clonal biases associated with monoclonal knockout cell lines. The product enables robust and reproducible experimental analysis of apoptosis execution, neurodegeneration pathways, and cancer cell death resistance mechanisms in a well-established human epithelial background.
The HeLa host cell line, derived in 1951 from Henrietta Lacks, is a widely utilized model in cancer biology. These cells display an HPV18-positive, p53-deficient, hyper-triploid karyotype with vigorous growth characteristics in adherent culture. As a cervical adenocarcinoma-derived epithelial cell line, HeLa provides a relevant cellular context for studying apoptosis signaling and the consequences of caspase-6 disruption within a malignant environment. The robust proliferation and ease of genetic manipulation make this host ideal for generating CRISPR knockout models.
CASP6 encodes caspase-6, an effector caspase that executes apoptosis by cleaving structural and regulatory proteins after aspartate residues. It is activated by initiator caspases-8 or -9, which assemble in response to death receptor engagement or mitochondrial cytochrome c release, respectively. Once active, caspase-6 processes substrates such as lamin A/C (LMNA), keratin 18 (KRT18), ??-tubulin (TUBA), PARP, and additional targets, leading to nuclear lamina disassembly and cytoskeletal collapse. Its activity is promoted by Fas/TNFR/FADD/caspase-8 and Apaf-1/cytochrome c/caspase-9 pathways and inhibited by XIAP and cIAP1/2. Beyond apoptosis, caspase-6 drives axon degeneration, linking it to Alzheimer’s, Huntington’s, and ALS.
In the HeLa cancer cell context, disruption of CASP6 provides a powerful tool for dissecting apoptosis resistance mechanisms frequently observed in tumor cells. Loss of effector caspase activity can confer resistance to death receptor- and chemotherapy-induced cell death, making this knockout model valuable for cancer biology and drug discovery. Moreover, as caspase-6 is implicated in pathological protein processing in neurodegeneration, these cells offer a unique platform for studying the non-apoptotic roles of caspase-6 in neuronal-like conditions when complemented with appropriate differentiation or reporter systems. The hyper-triploid nature of HeLa cells further allows for analysis of allele-specific effects and genetic compensation in polyclonal populations.
Researchers can employ these polyclonal knockout cells in diverse experimental workflows, including Western blotting to detect loss of cleaved substrates such as lamin A/C and keratin 18, Annexin V-based apoptosis assays, and luminogenic caspase activity measurements. Immunofluorescence staining for nuclear lamina or cytoskeletal markers reveals caspase-6-dependent phenotypes. These cells are suitable for drug screening evaluating caspase-6 activators or inhibitors in cancer and neurodegeneration. The polyclonal format ensures representation of various editing events, enabling robust statistical analysis of loss-of-function effects. For additional information, technical support, or custom requirements, please contact Ascent Research.
